tbuckley/cabot-search huggingface dataset:
P1.01-12 SWItch Maintenance PEmbrolizumab in Patients with Metastatic Non Small Cell Lung Cancer (SWIPE)
Authors: H. Charalambous, F. Kyriacou, I. Stylianou, P. Vogazianos, M. Allayioti, D. Vomvas, N. Katodritis, G. Orphanos
Journal: Journal of Thoracic Oncology (2018)
P1.01-53 Bone Metastases and Efficacy of Immunotherapy in Patients with Pretreated Advanced Non-Small-Cell Lung Cancer (NSCLC)
Authors: L. Landi, F. D'Incà, E. Cortesi, R. Chiari, F. Grossi, A. Delmonte, F. De Marinis, D. Signorelli, C. Dazzi, F. Sperandi, A. Catino, D. Giannarelli, H. Soto Parra, G. Minuti, P. Bordi, M.R. Migliorino, A. Palla, G. Tonini, F. Cognetti, A. Santoro, D. Tassinari, A. Scoppola, P. Bidoli, F. Piantedosi, M. Maio, L. Crinò, F. Cappuzzo
Journal: Journal of Thoracic Oncology (2018)
Tumor immunoevasion via acidosis-dependent induction of regulatory tumor-associated macrophages
Authors: Toszka Bohn, Steffen Rapp, Natascha Luther, Matthias Klein, Till-Julius Bruehl, Nobuhiko Kojima, Pamela Aranda Lopez, Jennifer Hahlbrock, Sabine Muth, Shogo Endo, Stefanie Pektor, Almut Brand, Kathrin Renner, Vanessa Popp, Katharina Gerlach, Dennis Vogel, Christina Lueckel, Danielle Arnold-Schild, Jacques Pouyssegur, Marina Kreutz, Magdalena Huber, Jochem Koenig, Benno Weigmann, Hans-Christian Probst, Esther von Stebut, Christian Becker, Hansjoerg Schild, Edgar Schmitt, Tobias Bopp
Journal: Nature Immunology (2018)
Understanding biological activity, tumor response and pseudoprogression in a phase-IIb study of MDNA55 in adults with recurrent or progressive glioblastoma (GB)
Authors: M.F. Bexon, A. Achrol, K. Bankiewicz, A. Brenner, N. Butowski, S. Kesari, F. Merchant, R. Merchant, D. Randazzo, M. Vogelbaum, M. Zabek, J. Sampson
Journal: Annals of Oncology (2018)
P1.01-89 Analysis and Monitoring CTCs and ctDNA in CSF Demonstrates Clinical Concordance in Tesevatinib Treated NSCLC Patients with LM
Authors: V. Singh, C.R. Vibat, M. Poyurovsky, L. Green, B. Mac Gillivray, D. Eiznhamer
Journal: Journal of Thoracic Oncology (2018)
P1.01-06 Plinabulin, a Novel Immuno-Oncology Agent Mitigates Docetaxel Chemotherapy -Induced-Neutropenia and -Thrombocytopenia in NSCLC Patients
Authors: D. Blayney, S. Ogenstad, Y. Shi, Q. Zhang, L. Du, L. Huang, R. Mohanlal
Journal: Journal of Thoracic Oncology (2018)
P1.03-13 eIF2β, A Subunit of Translation-Initiation Factor EIF2, as a Potential Therapeutic Target for Non-Small Cell Lung Cancer
Authors: D. Goto, I. Tanaka, M. Sato, T. Kato, A. Miyazawa, T. Hase, M. Morise, Y. Sekido, L. Girard, J. Minna, L. Byers, J. Heymach, K. Coombes, M. Kondo, Y. Hasegawa
Journal: Journal of Thoracic Oncology (2018)
Results of a phase I study of andecaliximab in combination with mFOLFOX6 and bevacizumab in patients with previously untreated metastatic colorectal cancer
Authors: H.-J. Lenz, H. Park, M.A. Shah, J.D. Berlin, D. Bruetman, J. Chaves, M. Gordon, R. Patel, A. Starodub, J. Liu, C. Baker Brachmann, P. Bhargava, Z.A. Wainberg, J. Bendell
Journal: Annals of Oncology (2018)
Bone Marrow–Derived Proangiogenic Cells Mediate Pulmonary Arteriole Stiffening via Serotonin 2B Receptor Dependent Mechanism
Authors: Nathaniel C. Bloodworth, Cynthia R. Clark, James D. West, J. Caleb Snider, Christa Gaskill, Sheila Shay, Christine Scott, Julie Bastarache, Santhi Gladson, Christy Moore, Reid D’Amico, Evan L. Brittain, Harikrishna Tanjore, Timothy S. Blackwell, Susan M. Majka, W. David Merryman
Journal: Circulation Research (2018)

Rationale: Pulmonary arterial hypertension is a deadly disease of the pulmonary vasculature for which no disease-modifying therapies exist. Small-vessel stiffening and remodeling are fundamental pathological features of pulmonary arterial hypertension that occur early and drive further endovascular cell dysfunction. Bone marrow (BM)–derived proangiogenic cells (PACs), a specialized heterogeneous subpopulation of myeloid lineage cells, are thought to play an important role in pathogenesis. Objective: To determine whether BM-derived PACs directly contributed to experimental pulmonary hypertension (PH) by promoting small-vessel stiffening through 5-HT 2B (serotonin 2B receptor)–mediated signaling. Methods and Results: We performed BM transplants using transgenic donor animals expressing diphtheria toxin secondary to activation of an endothelial-specific tamoxifen-inducible Cre and induced experimental PH using hypoxia with SU5416 to enhance endovascular injury and ablated BM-derived PACs, after which we measured right ventricular systolic pressures in a closed-chest procedure. BM-derived PAC lineage tracing was accomplished by transplanting BM from transgenic donor animals with fluorescently labeled hematopoietic cells and treating mice with a 5-HT 2B antagonist. BM-derived PAC ablation both prevented and reversed experimental PH with SU5416-enhanced endovascular injury, reducing the number of muscularized pulmonary arterioles and normalizing arteriole stiffness as measured by atomic force microscopy. Similarly, treatment with a pharmacological antagonist of 5-HT 2B also prevented experimental PH, reducing the number and stiffness of muscularized pulmonary arterioles. PACs accelerated pulmonary microvascular endothelial cell injury response in vitro, and the presence of BM-derived PACs significantly correlated with stiffer pulmonary arterioles in pulmonary arterial hypertension patients and mice with experimental PH. RNA sequencing of BM-derived PACs showed that 5-HT 2B antagonism significantly altered biologic pathways regulating cell proliferation, locomotion and migration, and cytokine production and response to cytokine stimulus. Conclusions: Together, our findings illustrate that BM-derived PACs directly contribute to experimental PH with SU5416-enhanced endovascular injury by mediating small-vessel stiffening and remodeling in a 5-HT 2B signaling–dependent manner.
Antibiotics may enhance the efficacy of gemcitabine treatment for advanced pancreatic cancer
Authors: Y. Sunakawa, H. Arai, N. Izawa, T. Mizukami, Y. Horie, A. Doi, M. Hirakawa, T. Ogura, T. Tsuda, T.E. Nakajima
Journal: Annals of Oncology (2018)
A Multicenter Phase II Study of AMG 337 in Patients with <i>MET</i>-Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma and Other <i>MET</i>-Amplified Solid Tumors
Authors: Eric Van Cutsem, Boguslawa Karaszewska, Yoon-Koo Kang, Hyun Cheol Chung, Veena Shankaran, Salvatore Siena, Ning F. Go, Hui Yang, Marco Schupp, David Cunningham
Journal: Clinical Cancer Research (2018)

MET gene amplification is associated with poor prognosis in gastric/gastroesophageal junction/esophageal (G/GEJ/E) cancers. We determined antitumor activity, safety, and pharmacokinetics of the small-molecule MET inhibitor AMG 337 in MET-amplified G/GEJ/E adenocarcinoma or other solid tumors.Patients and Methods: In this phase II, single-arm study, adults with MET-amplified G/GEJ/E adenocarcinoma (cohort 1) or other MET-amplified solid tumors (cohort 2) received AMG 337 300 mg/day orally in 28-day cycles. The primary endpoint was objective response rate (ORR; cohort 1). Secondary endpoints included ORR (cohort 2), progression-free survival (PFS), overall survival (OS), and safety.Of 2101 patients screened for MET amplification, 132 were MET-amplified and 60 were enrolled: 45 in cohort 1, and 15 in cohort 2. Fifty-six patients (97%) had metastatic disease; 57 had prior lines of therapy (1 prior line, 29%; ≥2 prior lines, 69%). A protocol-permitted review showed efficacy that was lower-than-expected based on preliminary data from a first-in-human study, and enrollment was stopped. Fifty-eight patients received ≥1 AMG 337 dose. ORR in cohort 1 was 18% (8 partial responses). No responses were observed in cohort 2. Of 54 evaluable patients, median (95% CI) PFS and OS were 3.4 (2.2-5.0) and 7.9 (4.8-10.9) months, respectively. The most frequent adverse events (AEs) were headache (60%), nausea (38%), vomiting (38%), and abdominal pain, decreased appetite, and peripheral edema (33% each); 71% had grade ≥3 AEs and 59% had serious AEs.AMG 337 showed antitumor activity in MET-amplified G/GEJ/E adenocarcinoma but not in MET-amplified non-small-cell lung cancer.See related commentary by Ma, p. 2375.
FRI0709-HPR Levels of satisfaction with psoriatic arthritis (PSA) treatment and associated alignment between rheumatologists and their patients across latin america
Authors: F. Zazzetti, E.R. Soriano, D. Rocio Gil, J. Maldonado cocco, D. Vega Morales, I. Alves Pereira, G. Guerra, W. Bautista Molano, J.C. Cassola, V. Azevedo, L.M. Aldunate, S. Lobosco
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Objectives:</h3> To assess levels of rheumatologist and patient satisfaction with PsA treatment across Latin America and any disconnects that may exist between the two in real world clinical practice. <h3>Methods:</h3> Data from the 2015 PsA Disease Specific Programme (DSP), a cross-sectional, multi-national survey of patients and rheumatologists conducted in Argentina, Mexico, Colombia and Venezuela were analyzed. Rheumatologists (n=141) completed forms containing patient demographics, patient disease severity and treatment satisfaction. Patients self-reported their level of treatment satisfaction and disease severity. <h3>Results:</h3> A total of 293 PsA patients from across Latin America were included in this analysis. Current mean age was 49.9 years and 48.1% were female. Proportions of rheumatologists and patients reporting satisfaction with treatment were both similarly high (84% and 92% respectively), however current disease severity reporting differed more markedly between rheumatologists and patients (mild 78%/moderate-severe 22% rheumatologists vs. 63% mild/37% moderate-severe patients; p=0.002). When assessed for alignment, 19% of all rheumatologists and patients disagreed on the level of treatment satisfaction; 13% of this was due to rheumatologists stating greater dissatisfaction than their patients, with the remaining 6% due to patients stating greater dissatisfaction than their rheumatologists (p=0.0543). For current disease severity, 32% of all rheumatologists and patients disagreed; 25% due to patients stating greater severity than their rheumatologists, with 7% due to rheumatologists stating greater severity than their patients (p&lt;0.001). Of those patients for whom their rheumatologist was satisfied with treatment, 14% were classified as having moderate to severe PsA by that same physician. <h3>Conclusions:</h3> Despite many rheumatologists and their patients in Latin America reporting high levels of satisfaction with treatment, PsA patients can remain moderate to severe and disconnected from their physician. There is a need to improve physician/patient engagement as a means to improving clinical control. <h3>Disclosure of Interest:</h3> None declared
Sunscreen and facial skincare products in frontal fibrosing alopecia: a case–control study
Authors: W.C. Cranwell, R. Sinclair
Journal: British Journal of Dermatology (2018)

Since Kossard first described frontal fibrosing alopecia (FFA) in 1994, the incidence has increased worldwide (1).The pathophysiology remains unclear.Reports of familial FFA suggest a genetic component.Other investigators suggest hormonal, autoimmune and inflammatory processes.The epidemiology of the condition strongly implicates environmental factors.Aldoori et al reported a possible
The cancer molecular screening and therapeutics program (MoST): A molecular screening platform with multiple, parallel, signal-seeking therapeutic substudies
Authors: S. Thavaneswaran, L. Sebastian, M. Ballinger, M. Cowley, J. Grady, A. Joshua, C. Lee, K. Sjoquist, W. Hague, J. Simes, D. Thomas
Journal: Annals of Oncology (2018)
P3.08-04 OMEGA, A Randomized Trial of Local Ablative Therapy Vs. Conventional Treatment in Oligometastatic NSCLC – Trial in Progress
Authors: M. Infante, E. Bria, S. Novello, U. Pastorino, L. Buffoni, M. Scorsetti, M. Alloisio, A. Ardizzoni, A. Santo, S. Pilotto, F. Facciolo, D. Giannarelli
Journal: Journal of Thoracic Oncology (2018)
<i>Clostridioides difficile</i> uses amino acids associated with gut microbial dysbiosis in a subset of patients with diarrhea
Authors: Eric J. Battaglioli, Vanessa L. Hale, Jun Chen, Patricio Jeraldo, Coral Ruiz-Mojica, Bradley A. Schmidt, Vayu M. Rekdal, Lisa M. Till, Lutfi Huq, Samuel A. Smits, William J. Moor, Yava Jones-Hall, Thomas Smyrk, Sahil Khanna, Darrell S. Pardi, Madhusudan Grover, Robin Patel, Nicholas Chia, Heidi Nelson, Justin L. Sonnenburg, Gianrico Farrugia, Purna C. Kashyap
Journal: Science Translational Medicine (2018)

Increased amino acids in the dysbiotic gut influences susceptibility to Clostridioides difficile infection in mice and humans.
Hybrid Capture–Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non–Small Cell Lung Cancer
Authors: Alexa B. Schrock, Allison Welsh, Jon H. Chung, Dean Pavlick, Eric H. Bernicker, Benjamin C. Creelan, Brady Forcier, Jeffrey S. Ross, Philip J. Stephens, Siraj M. Ali, Ibiayi Dagogo-Jack, Alice T. Shaw, Tianhong Li, Sai-Hong Ignatius Ou, Vincent A. Miller
Journal: Journal of Thoracic Oncology (2018)

IntroductionGenomic profiling informs selection of matched targeted therapies as part of routine clinical care in NSCLC. Tissue biopsy is the criterion standard; however, genomic profiling of blood-derived circulating tumor DNA (ctDNA) has emerged as a minimally invasive alternative.MethodsHybrid capture–based genomic profiling of 62 genes was performed on blood-based ctDNA from 1552 patients with NSCLC.ResultsEvidence of ctDNA was detected in 80% of samples, and in 86% of these cases, at least one reportable genomic alteration (GA) was detected. Frequently altered genes were tumor protein p53 gene (TP53) (59%), EGFR (25%), and KRAS (17%). Comparative analysis with a tissue genomic database (N = 21,500) showed similar frequencies of GAs per gene, although KRAS mutation and EGFR T790M were more frequent in tissue and ctDNA, respectively (both p < 0.0001), likely reflecting the use of liquid versus tissue biopsy after relapse during targeted therapy. In temporally matched ctDNA and tissue samples from 33 patients with evidence of ctDNA in their blood, 64% of GAs detected in tissue were also detected in ctDNA, including 78% of short variants (58 of 74) and 100% of rearrangements (four of four), but only 16% of amplifications (four of 25).ConclusionsGenomic profiling of ctDNA detected clinically relevant GAs in a significant subset of NSCLC cases. Most alterations detected in matched tissue were also detected in ctDNA. These results suggest the utility of ctDNA testing in advanced NSCLC as a complementary approach to tissue testing. Blood-based ctDNA testing may be particularly useful at the time of progression during targeted therapy.
P2.17-13 Genome-Wide Copy Number Alterations Profiling Predict Efficacy of Resected Stage II-IIIA Lung Adenocarcinoma
Authors: X. Han, Q. Tan, T. Xiong, S. Yang, W. Dai, D. Lin, Y. Zhou, H. Lin, Y. Shi
Journal: Journal of Thoracic Oncology (2018)
Initial results of phase I study of DCC-2618, a broad-spectrum KIT and PDGFRa inhibitor, in patients (pts) with gastrointestinal stromal tumor (GIST) by number of prior regimens
Authors: S. George, M. Heinrich, P. Chi, A. Razak, M. von Mehren, M. Gordon, K.N. Ganjoo, N. Somaiah, J.C. Trent, J. Rodon Ahnert, J. Wolf, R. Ruiz-Soto, O. Rosen, F. Janku
Journal: Annals of Oncology (2018)
P2.01-107 Analysis of Mutation Detection by ctDNA on the Basis of Metastatic Sites in Lung Adenocarcinoma Patients
Authors: R. Guo, H. Xu, J. Zhang, X. Ai, L. Liu, J. Zhao, X. Dong, L. Miao, R. Chen, X. Xia
Journal: Journal of Thoracic Oncology (2018)
What information and features do young and older adults with cancer want in their hospital-based social media cancer resource?
Authors: C.B. Paulo, L. Eng, L. Mitchell, I. Geist, S. Kassirian, A. Magony, E.C. Smith, C. Brown, M. Liang, K. Hueniken, D. Yang, W. Xu, G. Liu, A. Gupta, J. Bender
Journal: Annals of Oncology (2018)
Disseminated mucormycosis due to Lichtheimia corymbifera during ibrutinib treatment for relapsed chronic lymphocytic leukaemia: a case report
Authors: O. Grossi, S. Pineau, S. Sadot-Lebouvier, B. Hay, J. Delaunay, A.-F. Miailhe, C. Bretonnière, F. Jeddi, R.A. Lavergne, P. Le Pape
Journal: Clinical Microbiology and Infection (2018)
START: A randomized phase II study in patients with triple negative, androgen receptor positive locally recurrent (unresectable) or metastatic breast cancer treated with darolutamide or capecitabine (UCBG-306)
Authors: H. Bonnefoi, C. Levy, G. MacGrogan, T. Grellety, B. Asselain, M. Pulido, S. Everhard, J. Lemonnier, A. Gonçalves
Journal: Annals of Oncology (2018)
The use of patient reported outcome (PRO) instruments in immune checkpoint inhibitor (ICI) therapy for cancer: A systematic review
Authors: S. Colomer-Lahiguera, D. Bryant-Lukosius, S. Rietkoetter, L. Martelli, K. Ribi, A. Orcurto, R. Juergens, M. Eicher
Journal: Annals of Oncology (2018)
Avelumab in European patients (pts) with metastatic Merkel cell carcinoma (mMCC): Experience from an ad-hoc expanded access program (EAP)
Authors: P. Nathan, V. Kasturi, L. Dirix, E. Fenig, P.A. Ascierto, M. Hennessy, J. Reed, A. Engelsberg, S. Hariharan, C. Lebbé
Journal: Annals of Oncology (2018)
Can Better Cardiovascular Care Close the Mortality Gap for People With Schizophrenia?
Authors: Benjamin G. Druss
Journal: JAMA Psychiatry (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Debunking the myths about training load, injury and performance: empirical evidence, hot topics and recommendations for practitioners
Authors: Tim J Gabbett
Journal: British Journal of Sports Medicine (2018)

A substantial amount of research has tested the relationship between training load and injury.1 Given that sports injuries compromise team success,2 3 team administrators, players and coaches are now interested in this field. As team injury data are widely available through various internet sources (eg, Man Games Lost, https://www.mangameslost.com/), sports medicine staff are commonly evaluated based on the number of injuries sustained (or not sustained) by their playing rosters.

A search of the ‘PubMed’ database shows that in the past 18 years, there has been a rapid growth in ‘training load’ and ‘injury’ research, increasing from 9 papers in 2000 to 145 in 2017 (figure 1). Despite this growing body of literature, evidence-based guidelines to reduce workload-related injury are often poorly implemented due to the level of expertise or understanding of the high-performance team (including the skill coaches, strength and conditioning or medical staff) or their individual beliefs and experiences (cognitive biases, confirmation biases). This can lead to a disconnect between the evidence supporting training load and its role in injury, and the actual training programmes prescribed.4 Five common myths and misconceptions about training load and its role in injury and performance are reviewed in this paper.



Figure 1 
Growth in research including the keywords ‘training’ AND ‘injury’ since 2000.



The relationship between training, performance and injury has been of interest to researchers and practitioners for considerable time.1 5–15 Both individual16 and team17–19 performance can be explained, at least in part by training load, with higher training loads generally associated with better performance. Equally, a large body of evidence has emerged suggesting that inappropriately prescribed training load may increase injury risk20–25 and pain.26 Based on these findings, a myopic view would be that ‘load’ explains all injuries.

The multifactorial determinants of both performance and …
Assessment and treatment of breakthrough cancer pain in Spain: A self-audit study
Authors: R. Lopez Lopez, J.J. Reina Zoilo, D. Monge, F. Caballero, V. Guillem Porta, E. Aranda Aguilar, A. Carrato Mena, E. Diaz Rubio, J. Garcia Foncillas, M. Feyjoo, C. Camps
Journal: Annals of Oncology (2018)
P2.01-23 Baseline Plasma Biomarkers Predict Long-Term Responses to ALK-TKIs in ALK+ Advanced Non-Small Cell Lung Cancer (NSCLC)
Authors: M. Couetoux Du Tertre, M. Marques, L. Izzi, L. Tremblay, N. Bouchard, R. Diaconescu, N. Blais, C. Hoffert, A. Srivastava, S. McNamara, G. Batist, V. Cohen, J. Agulnik
Journal: Journal of Thoracic Oncology (2018)
PL02.09 Nintedanib + Pemetrexed/Cisplatin in Patients with Unresectable MPM: Phase III Results from the LUME-Meso Trial
Authors: G. Scagliotti, R. Gaafar, A. Nowak, T. Nakano, J. Van Meerbeeck, S. Popat, N. Vogelzang, F. Grosso, R. Aboelhassan, M. Jakopovic, G. Ceresoli, P. Taylor, F. Orlandi, D. Fennell, S. Novello, A. Scherpereel, U. Von Wangenheim, M. Kim, J. Barrueco, A. Tsao
Journal: Journal of Thoracic Oncology (2018)
Immune prognostic index (IPI) and hyper-progressive disease (HPD) in patients (pts) exposed to targeted agents (TAs) in phase I trials (Ph1T): Can lessons from immune checkpoint inhibitors (ICIs) be translated to other scenarios?
Authors: I. Matos Garcia, A. Azaro, C. Viaplana, C. Hierro, J. Martin-Liberal, I. Brana, I. Gardeazabal, P. Gomila, M. Vieito Villar, M. Ochoa De Olza Amat, E. Elez Fernandez, M. Oliveira, A. Oaknin, H. Verdaguer, A. Navarro Mendivil, M. Alsina, J. Tabernero, T. Macarulla Mercade, R. Dienstmann, E. Garralda
Journal: Annals of Oncology (2018)
MA02.10 The First Year of Implementing a Lung Cancer Screening Program in an Urban Safety-Net Health System
Authors: H. Hamann, S. Lee, T. Browning, C. Chavez, J. Sanders, S. Abbara, D. Balis, H. Chiu, B. Moran, N. Santini, D. Gerber
Journal: Journal of Thoracic Oncology (2018)
A randomized phase II trial of erlotinib or erlotinib and bevacizumab in patients with advanced EGFR mutant non-small cell lung cancer (NSCLC)
Authors: T.E. Stinchcombe, P.A. Janne, X. Wang, E.M. Bertino, J.M. Weiss, L. Bazhenova, L. Gu, C.J. Lau, C.P. Paweletz, A.J. Jaslowski, G.J. Gerstner, M.Q. Baggstrom, S.L. Graziano, J. Bearden, E.E. Vokes
Journal: Annals of Oncology (2018)
An open-label, multicenter, phase I study of ABBV-399 (telisotuzumab vedotin, teliso-V) as monotherapy (T) and in combination with erlotinib (T+E) in non-small cell lung cancer (NSCLC)
Authors: R. Camidge, R.S. Heist, J. Goldman, E. Angevin, J. Strickler, D. Morgensztern, M. Barve, T.M. Bauer, E.E. Vokes, T. Yi, M. Motwani, A. Parikh, J. Wu, K. Kelly
Journal: Annals of Oncology (2018)
P3.07-05 Can Improving Working Partnerships with Primary Care Prevent Avoidable Emergency Admissions for Patients with Lung Cancer?
Authors: J. Morley, V. Anderson, V. Beattie, K. Clayton, D. Denby, M. Eaton, S. Glover, A. Griffiths, N. Maddock, J. Mcadam, S. Morgan, T. Perkins, S. Phillips, B. Pugh, P. Rees, J. Roberts, W. Robinson, P. Rose
Journal: Journal of Thoracic Oncology (2018)
Mismatch repair deficiency (MMRd) in glioma patients (PTS): Frequency and correlation with clinical, histological and molecular characteristics
Authors: G. Lombardi, M. Caccese, M. Simonelli, M. Fassan, P. Persico, E. Lorenzi, R. Bertorelle, M.P. Gardiman, L. Bellu, A. Pambuku, A. Santoro, V. Zagonel
Journal: Annals of Oncology (2018)